Echocardiography

CorVista Health Announces AHA Presentation of Machine Learning to Detect Pulmonary Hypertension at Point-of-Care

Retrieved on: 
Sunday, November 12, 2023

CorVista Health AHA Presentation--Machine Learning to Detect Pulmonary Hypertension at Point of Care. Presented by Dr. Charles Bridges. (Photo: Business Wire)

Key Points: 
  • CorVista Health, Inc. , a leading digital health company dedicated to improving cardiovascular disease diagnosis, is pleased to announce the presentation of Machine Learning to Detect Pulmonary Hypertension data at AHA.
  • View the full release here: https://www.businesswire.com/news/home/20231112489250/en/
    CorVista Health AHA Presentation--Machine Learning to Detect Pulmonary Hypertension at Point of Care.
  • (Photo: Business Wire)
    “We are pleased to present this important data at this year’s AHA meeting.” said Don Crawford, President and CEO of CorVista Health.
  • “We believe the CorVista System® can make a tremendous impact to patients suffering from pulmonary hypertension, especially in rural and underserved populations.”

Visage Soars with CloudPACS at RSNA 2023

Retrieved on: 
Thursday, November 9, 2023

SAN DIEGO, Nov. 9, 2023 /PRNewswire/ -- Visage Imaging, Inc. ("Visage"), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has announced it will be showcasing a series of exciting new product additions and innovations, as well as the industry-leading Visage® 7 Enterprise Imaging Platform ("Visage 7"), engineered for CloudPACS (cloudpacs.com™) at the Radiological Society of North America (RSNA) 2023 annual meeting, Booth 4329, McCormick Place South Hall (Chicago, IL) from Sunday, November 26 – Wednesday, November 29, 2023.

Key Points: 
  • At RSNA 2023, in addition to demonstrating the breadth of the Visage 7 platform, Visage is introducing multiple new solutions and offering customer insights into Visage 7, including:
    Visage 7 | Cardiology Imaging.
  • In the Visage booth, Visage will be demonstrating Visage Breast Density and numerous AI algorithms based on Visage AI Accelerator* global customer research collaborations, as well as third-party AI solutions.
  • To schedule a priority demonstration of Visage 7 at RSNA 2023, please click here for additional details.
  • If you are unable to attend RSNA 2023, but would like to schedule a demonstration of Visage 7, please click here .

Attralus Announces Publication of Two Studies Evaluating Iodine (124I) Evuzamitide (AT-01) using PET/CT in the Journal of American College of Cardiology (JACC CV Imaging)

Retrieved on: 
Tuesday, November 7, 2023

124I-evuzamitide may be more sensitive than standard diagnostics, with cardiac uptake shown in ATTR patients who had negative 99mTc-PYP scans.

Key Points: 
  • 124I-evuzamitide may be more sensitive than standard diagnostics, with cardiac uptake shown in ATTR patients who had negative 99mTc-PYP scans.
  • The manuscripts from Brigham and Women’s Hospital (BWH) and from the University of Tennessee Graduate School of Medicine were published in the Journal of American College of Cardiology – Cardiovascular Imaging (JACC CV Imaging).
  • The manuscripts, entitled “Cardiac Amyloid Quantification Using 124I-Evuzamitide (124I-P5+14) Versus 18F-Florbetapir” and “Cardiac Amyloid Detection by PET/CT Imaging of Iodine (124I) Evuzamitide (124I-p5+14): A Phase 1/2 Study,” have been published online.
  • These studies suggest that 124I-evuzamitide is a promising novel radiotracer to detect and quantify cardiac amyloid in multiple types of amyloidosis.

JenaValve Announces Late-Breaking Data from the ALIGN-AR Pivotal Trial Meeting Safety and Efficacy Endpoints

Retrieved on: 
Tuesday, October 24, 2023

The trial met prespecified non-inferiority criteria for its primary safety endpoint and primary efficacy endpoint.

Key Points: 
  • The trial met prespecified non-inferiority criteria for its primary safety endpoint and primary efficacy endpoint.
  • Outcomes were presented by Dr. Vinod Thourani (Piedmont Heart Institute, Atlanta, GA) during the opening Late-Breaking Clinical Trial sessions at the 2023 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium in San Francisco, CA.
  • “We are encouraged to see the significant LV mass reduction at over 20% and substantial improvement in quality of life in the ALIGN-AR pivotal trial results,” said Torsten P. Vahl, MD, Principal Investigator of the ALIGN-AR trial.
  • Results from the study are intended to support a Premarket Approval submission to the U.S. Food and Drug Administration (FDA).

Hemet Global Medical Center Voted “Best Hospital” in the Inland Empire by Press-Enterprise Readers for 2023

Retrieved on: 
Tuesday, October 17, 2023

ORANGE, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Hemet Global Medical Center (“HGMC”), a KPC Health hospital, has been voted “Best Hospital” in the Inland Empire for 2023 by Press-Enterprise readers.

Key Points: 
  • ORANGE, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Hemet Global Medical Center (“HGMC”), a KPC Health hospital, has been voted “Best Hospital” in the Inland Empire for 2023 by Press-Enterprise readers.
  • The distinguished honor is part of the Press-Enterprise’s 28th Annual “Best of Inland Empire” Readers’ Choice awards for local businesses.
  • “Prior to KPC Health’s acquisition of Hemet Global Medical Center, this was a hospital on the brink of bankruptcy that many believed could not be saved,” said Dr. Kali P. Chaudhuri, Founder and Chairman of the KPC Group.
  • KPC Health’s current system of hospitals includes seven full-service acute care hospitals located throughout southern California, including Orange County Global Medical Center, Chapman Global Medical Center, Anaheim Global Medical Center, South Coast Global Medical Center, Hemet Global Medical Center, Menifee Global Medical Center, and Victor Valley Global Medical Center.

Rady Children's Hospital Appoints Adel Younoszai, MD, as Rady Children's Hospital Co-Director of the Heart Institute, and Division Chief of Cardiology, Department of Pediatrics, UC San Diego

Retrieved on: 
Tuesday, October 3, 2023

Dr. Younoszai will spearhead the evolution of the cardiology department by embracing the technological advancements to empower providers to deliver faster more effective care and improve outcomes.

Key Points: 
  • Dr. Younoszai will spearhead the evolution of the cardiology department by embracing the technological advancements to empower providers to deliver faster more effective care and improve outcomes.
  • "Dr. Younoszai's accomplishments in clinical care, research and in leadership roles are truly impressive."
  • "His accomplishments in clinical care, research and in leadership roles are truly impressive and we're so fortunate to have him join Rady Children's and UC San Diego."
  • "He will be a great Cardiology Chief for our institution, and he joins us at the right time.

Attralus Announces Presentation of Clinical Data for 124I-Evuzamitide (AT-01), a Novel Amyloid-Specific PET Imaging Agent, at the 28th Annual Scientific Session of the American Society of Nuclear Cardiology

Retrieved on: 
Monday, October 2, 2023

Attralus-Sponsored Test-Retest repeatability study demonstrates excellent repeatability and supports the potential use of AT-01 imaging to monitor disease progression in patients with cardiac amyloidosis.

Key Points: 
  • Attralus-Sponsored Test-Retest repeatability study demonstrates excellent repeatability and supports the potential use of AT-01 imaging to monitor disease progression in patients with cardiac amyloidosis.
  • AT-01 uptake in cardiac amyloidosis shows moderate and statistically significant correlations with traditional measures of cardiac structure and function.
  • These data were included in oral and poster presentations at the 28th Annual Scientific Session of the American Society of Nuclear Cardiology (ASNC) taking place September 29-October 1, 2023, in Toronto, Canada.
  • These findings support the potential use of this novel imaging agent to monitor disease progression in patients with cardiac amyloidosis.

Icahn School of Medicine at Mount Sinai Awarded $10.2 Million NIH Grant to Explore the Early Signs of Arrhythmic Mitral Valve Prolapse

Retrieved on: 
Tuesday, September 26, 2023

NEW YORK, Sept. 26, 2023 /PRNewswire-PRWeb/ -- Researchers at the Icahn School of Medicine at Mount Sinai have been awarded a $10.2 million grant from the National Heart, Lung and Blood Institute of the National Institutes of Health to investigate risk factors for malignant arrhythmias in mitral valve prolapse. This work aims to develop a better understanding of the condition and novel solutions to improve patient outcomes.

Key Points: 
  • The grant is a collaboration between four Icahn Mount Sinai specialties: Cardiac Electrophysiology, Cardiology, Cardiovascular Surgery, and the BioMedical Engineering and Imaging Institute (BMEII).
  • The grant is a collaboration between four Icahn Mount Sinai specialties: Cardiac Electrophysiology, Cardiology, Cardiovascular Surgery, and the BioMedical Engineering and Imaging Institute (BMEII).
  • In the United States, it is estimated that between 7 and 9 million people have mitral valve prolapse, the most common form of valve disease.
  • Mitral valve prolapse occurs when two flaps within the mitral valve don't close smoothly or evenly, but instead bulge (prolapse) upward into the left atrium when the heart contracts.

ModMed Introduces Maternal Fetal Medicine Addition to its OBGYN EHR Solution

Retrieved on: 
Tuesday, September 19, 2023

Medical practice leader, ModMed® , announced today the addition of maternal fetal medicine (MFM) capabilities into its electronic health record (EHR) suite for OBGYNs.

Key Points: 
  • Medical practice leader, ModMed® , announced today the addition of maternal fetal medicine (MFM) capabilities into its electronic health record (EHR) suite for OBGYNs.
  • View the full release here: https://www.businesswire.com/news/home/20230919581279/en/
    ModMed Introduces Maternal Fetal Medicine Addition to its OBGYN EHR Solution (Graphic: Business Wire)
    "ModMed's MFM incorporation into the OBGYN-EHR suite represents a significant advancement in providing comprehensive care and seamless communication between healthcare professionals," said Dr. Nigel Spier, Medical Director of OBGYN at ModMed.
  • Heather Stanley-Christian, MD, at Unity Maternal Fetal Medicine commented, “I've been thoroughly impressed by ModMed's OBGYN Practice Management software.
  • For more information about the ModMed OBGYN suite, please visit ModMed at modmed.com/resources/obgyn .

Therapeutic Solutions International Recruits Internationally Renowned Stem Cell Clinician and San Diego Top Doctor to Scientific Advisory Board

Retrieved on: 
Monday, September 18, 2023

Therapeutic Solutions International, Inc. (TSOI), announced today the appointment of internationally renowned stem cell therapist Dr. Navneet Boddu to the Company’s Scientific Advisory Board.

Key Points: 
  • Therapeutic Solutions International, Inc. (TSOI), announced today the appointment of internationally renowned stem cell therapist Dr. Navneet Boddu to the Company’s Scientific Advisory Board.
  • Dr. Boddu previously obtained for Therapeutic Solutions International Emergency IND approval to treat a patient with COVID-19 using JadiCells.
  • Therapeutic Solutions International plans to expand ongoing patient access to JadiCells as it advances in their development.
  • “Dr.